Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that a first dosing has been achieved in the previously announced early feasibility study of its Targeted Hyperthermia Therapy (“THT”) cancer treatment.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, announces that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Therapy (“THT”) cancer treatment.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, today announced that it has entered into a clinical trial agreement for an early feasibility study clinical trial of its Targeted Hyperthermia Therapy (“THT”). Sona has engaged Bradford Hill Investigacion Clinica (“Bradford Hill”) in Santiago, Chile for a study of Sona’s THT treatment for up to ten patients with advanced melanoma.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold nanorods, conducted by CBSET, Inc.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce the successful completion of bacterial endotoxin testing (“BET”) on Sona’s uniquely biocompatible gold nanorods using the Limulus Amebocyte Lysate (“LAL”) method at a leading global provider of laboratory testing and expert advisory services for MedTech and pharmaceutical companies based in the US.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (“Sona”) announce today that they have entered into a Research Agreement (“Agreement”) to collaborate on the development of new cancer therapeutics based on BioVaxys’ DPX™ Immune Educating Platform (“DPX”) in combination with Sona’s Targeted Hyperthermia Therapy™ (“THT”), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona’s proprietary biocompatible Gold Nanorod (“GNR”) technology which elicits a strong immune response.
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) announces that it has granted 2,135,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) of which 1,855,0000 have been granted to Directors and Officers. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company’s Stock Option Plan.
Halifax, Nova Scotia – (Newsfile Corp. – March 19, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to provide updated data confirming efficacy of its Targeted Hyperthermia Therapy (“THT”) cancer treatment in an immunotherapy resistant cancer. In this follow-up data to the previously released preliminary study (see press release dated December 11, 2024), again using an industry-standard, immunotherapy resistant, CT-26 colon cancer model, Sona’s THT cancer treatment was 100% effective in activating a strong, effective immune system response. In these experiments, animals treated with a PD-1 checkpoint inhibitor, a standard of care immunotherapy, experienced no benefit with tumors growing similarly to tumors in the control group of untreated animals. However, in a new, second cohort of eight animals first treated with Sona’s THT and then treated with a PD-1 inhibitor, 100% of animals responded demonstrating near complete arrest in tumor growth in the majority of animals as highlighted by the dashed green line in Figure 1, below.
Halifax, Nova Scotia – (Newsfile Corp. – February 12, 2025) – Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that recently published findings from its “Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors” study will be presented at the International 19th Canadian Melanoma Conference on February 20th in Vancouver. Sona’s Chief Medical Officer, Dr. Carman Giacomantonio, a planning committee member for this conference, and Dr. Barry Kennedy, of The Giacomantonio Immuno-Oncology Research Group, will present both poster and oral presentations.
Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been published in the peer-reviewed scientific journal, Frontiers in Immunology. This research article includes new follow-up data which provides a comprehensive analysis of the immunity activated by Sona’s Targeted Hyperthermia Therapy (“THT”). The published manuscript titled, “Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors” is available online in electronic form here and will be in print in its upcoming issue of Frontiers in Immunology – Cancer Immunology and Immunotherapy. Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology.